for the three months ended
|
|
for the six months ended
|
||||||
| In 000€ | 2023 |
|
2022 |
|
2023 |
|
2022 |
|
| Net profit (loss) for the period | (494) |
896 |
3,221 |
1,023 |
||||
| Income taxes | 532 |
600 |
1,249 |
898 |
||||
| Financial expenses | 670 |
1,320 |
2,045 |
2,561 |
||||
| Financial income | (1,305) |
(3,901) |
(2,114) |
(5,517) |
||||
| Depreciation and amortization | 5,353 |
5,374 |
10,664 |
10,816 |
||||
| EBITDA | 4,755 |
4,289 |
15,066 |
9,780 |
||||
| Share-based compensation expense (1) | - |
(49) |
- |
(97) |
||||
| Adjusted EBITDA | 4,755 |
4,240 |
15,066 |
9,683 |
||||
| (1) Share-based compensation expense represents the cost of equity-settled and share-based payments to employees. |
Segment P&L (Unaudited)
| In 000€ | Materialise
Software |
Materialise
Medical |
Materialise
Manufacturing |
Total
segments |
Unallocated (1) | Consolidated | ||||||
| For the three months ended June 30, 2023 | ||||||||||||
| Revenues | 11,030 |
24,945 |
28,835 |
64,810 |
0 |
64,810 |
||||||
| Segment (adj) EBITDA | 1,973 |
2,683 |
2,708 |
7,364 |
(2,608) |
4,755 |
||||||
| Segment (adj) EBITDA % | 17.9% |
10.8% |
9.4% |
11.4% |
7.3% |
|||||||
| For the three months ended June 30, 2022 | ||||||||||||
| Revenues | 10,642 |
20,855 |
26,574 |
58,070 |
0 |
58,070 |
||||||
| Segment (adj) EBITDA | 821 |
4,474 |
1,581 |
6,876 |
(2,636) |
4,240 |
||||||
| Segment (adj) EBITDA % | 7.7% |
21.5% |
5.9% |
11.8% |
7.3% |
|||||||
| In 000€ | Materialise
Software |
Materialise
Medical |
Materialise
Manufacturing |
Total
segments |
Unallocated
(1) |
Consolidated | ||||||
| For the six months ended June 30, 2023 | ||||||||||||
| Revenues | 22,381 |
49,265 |
59,056 |
130,702 |
0 |
130,702 |
||||||
| Segment (adj) EBITDA | 4,409 |
10,035 |
5,906 |
20,350 |
(5,285) |
15,066 |
||||||
| Segment (adj) EBITDA % | 19.7% |
20.4% |
10.0% |
15.6% |
11.5% |
|||||||
| For the six months ended June 30, 2022 | ||||||||||||
| Revenues | 21,125 |
39,201 |
50,705 |
111,032 |
0 |
111,032 |
||||||
| Segment (adj) EBITDA | 2,753 |
7,701 |
4,192 |
14,647 |
(4,963) |
9,683 |
||||||
| Segment (adj) EBITDA % | 13.0% |
19.6% |
8.3% |
13.2% |
8.7% |
| (1) Unallocated segment adjusted EBITDA consists of corporate research and development and corporate other operating income (expense), and the added share-based compensation expenses, acquisition related expenses of business combinations, impairments and fair value of business combinations that are included in Adjusted EBITDA. |
